コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 are showing great potential in improving the drug discovery process.
2 roducing these kinetic assays earlier in the drug discovery process.
3 ime for providing metabolism feedback to the drug discovery process.
4 e potential to become a valuable tool in the drug discovery process.
5 h to the biology of this organism and to the drug discovery process.
6 e usefulness of the SAR by NMR method in the drug discovery process.
7 lexes will be an important component of this drug discovery process.
8 ch for novel leads is a critical step in the drug discovery process.
9 2D cultures to translate targets during the drug discovery process.
10 structural barriers often encountered in the drug discovery process.
11 cilitating hit or lead identification in the drug discovery process.
12 ired, representing a major bottleneck in the drug discovery process.
13 the potential to speed up and smooth out the drug discovery process.
14 ntact proteins commonly performed within the drug discovery process.
15 teractions (DTI) is an important part of the drug discovery process.
16 nal antibodies (mAbs) generated in the early drug discovery process.
17 ems that are commonly encountered during the drug discovery process.
18 ional and experimental techniques during the drug discovery process.
19 potential to be used in early stages of the drug discovery process.
20 calculations can play a valuable role in the drug discovery process.
21 ely used for hit identification in the early drug discovery process.
22 rategy employed by medicinal chemists in the drug discovery process.
23 n-ligand binding affinity and accelerate the drug discovery process.
24 m of disease pathogenesis and accelerate the drug discovery process.
25 understanding of function to accelerate the drug discovery process.
26 ing this challenge could greatly benefit the drug discovery process.
27 achine learning has been introduced into the drug discovery process.
28 ains a major challenge that is hindering the drug discovery process.
29 mixtures have become important tools in the drug discovery process.
30 tation of computational methodologies in the drug discovery process.
31 in target space at an early stage during the drug discovery process.
32 tors, highlighting key considerations in the drug discovery process.
33 roaches can greatly speed up the traditional drug discovery process.
34 nt but overlapping levels of openness in the drug discovery process.
35 core and the experimental data to impact the drug discovery process.
36 as novel imaging platforms to facilitate the drug discovery process.
37 and only the best compounds progress in the drug discovery process.
38 onstrating the plugin's utility in the early drug discovery process.
39 rapies and is also a constituent part of the drug discovery process.
40 l relevance to the successful outcome of the drug discovery process.
41 his necessitates different approaches to the drug discovery process.
42 iology of psychiatric illness and aid in the drug discovery process.
43 physiologically relevant human cells in the drug discovery process.
44 st lead series during the early stage of the drug discovery process.
45 ctivity that is useful for many steps in the drug discovery process.
46 y polypharmacological compounds early in the drug discovery process.
47 rged as an especially important facet of the drug discovery process.
48 k for candidate drugs, thus facilitating the drug discovery process.
49 nd and higher cost-to-return benefits in the drug discovery process.
50 ased single cell analysis can bring into the drug discovery process.
51 xpression profiling across all phases of the drug discovery process.
52 ligands and receptors are often ignored in a drug discovery process.
53 ing is being routinely incorporated into the drug discovery process.
54 entify substrates, and this can speed up the drug discovery process.
55 put screening of reactive metabolites in the drug discovery process.
56 cceptable attrition rates in the preclinical drug discovery process.
57 atalyzed reactions could thus facilitate the drug discovery process.
58 a new tool facilitating the structure-based drug discovery process.
59 and are typically the limiting factor in the drug discovery process.
60 ield and their potential use in the oncology drug discovery process.
61 otential targets is an important step in the drug discovery process.
62 nated from consideration much earlier in the drug discovery process.
63 ols in combating late-stage attrition in the drug discovery process.
64 tor interactions are poor candidates for the drug discovery process.
65 o purification that can be used to guide the drug discovery process.
66 ntinues to be one of the main drivers in the drug discovery process.
67 complexes is a critical step in the rational drug discovery process.
68 s for hERG channel activity early during the drug discovery process.
69 ese systems is to inspire and accelerate the drug discovery process.
70 nerating components of the ADME profile in a drug discovery process.
71 , new strategies are required to advance the drug discovery process.
72 nction with mass spectrometry throughout the drug discovery process.
73 t would bypass the time-consuming and costly drug-discovery process.
74 ease and acting as a pivotal enabler for the drug-discovery process.
75 s will prove to be valuable additions to the drug-discovery process.
76 iction to accelerate the early stages of the drug-discovery process.
77 S) methods can drastically accelerate global drug discovery processes.
79 t may become important lead compounds in the drug discovery process aimed at developing new treatment
80 s significant potential for streamlining the drug discovery process, allowing researchers to focus on
82 a for the application of metabolomics in the drug discovery process and in personalized medicine.
83 igand binding modes is a crucial step in the drug discovery process and is especially important in ca
84 knowledge and infrastructure to expedite the drug discovery process and reduce costs, drug repurposin
86 tions that significantly help accelerate the drug discovery process and scientific research >29.9 m d
87 e conventional one-drug-one-gene-one-disease drug discovery process and single-indication polypharmac
88 power of including molecular dynamics in the drug discovery process and that this specific, clinicall
89 interactions (DTIs) in silico can guide the drug discovery process and thus facilitate drug developm
90 y had a positive impact on all stages of the drug discovery process and, increasingly, on the drug de
91 and validation remain difficult steps in the drug discovery process, and uncovering the core genes an
92 ity-oriented synthesis and their role in the drug discovery process are presented in this review.
95 n aryl fragments is a valuable aspect of the drug discovery process, but current strategies require t
96 human physiology, are starting to impact the drug discovery process, but their implementation has bee
97 binatorial chemistry has deeply impacted the drug discovery process by accelerating the synthesis and
98 ology and proposes strategies to improve the drug discovery process by enriching the pipeline of prom
99 mprove and accelerate the early antimalarial drug discovery process by identifying new, essential, dr
100 on Portal (TBEP), designed to accelerate the drug discovery process by integrating large-scale biomed
101 In short, microarrays are redefining the drug discovery process by providing greater knowledge at
102 rom hits to lead compounds, accelerating the drug discovery process by rapidly and reliably evaluatin
103 logical imaging into the early stages of the drug discovery process can provide invaluable informatio
105 has been suggested in various stages of the drug discovery process due to low sample consumption and
107 cation of novel chemical matter in the early drug discovery process enabled by parallel screening of
109 edicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural dise
111 natural products in order to accelerate the drug discovery process for high-throughput screening in
112 thus representing new lead compounds in the drug discovery process for the treatment of Human Africa
113 ed to other MBLs and in this way improve the drug discovery process for this important class of drug
115 gh-throughput screening (HTS) systems in the drug discovery process has resulted in an increasing nee
116 ations about significant improvements in the drug discovery process, healthcare and economic developm
117 eutic compounds is starting to influence the drug discovery process; however, the use of these cells
118 d excretion) models may be used early in the drug discovery process in order to flag drug candidates
119 e of disease-relevant human biology into the drug discovery process, informing target and compound va
127 f metabolomics as a routine component of the drug discovery process may provide some solutions to the
128 Incorporating these findings in the cancer drug discovery process might lead to better therapeutics
129 ctural arrangements is central to the modern drug discovery process, necessitating de novo synthesis
130 gands to protein targets can democratize the drug discovery process, presenting new opportunities for
131 l integration of these technologies into the drug discovery process provides the promise of increased
132 s have been applied at several stages of the drug discovery process, ranging from target identificati
134 ening for enzyme discovery, engineering, and drug discovery processes require simple, fast, and sensi
136 eriences on key stages in the small-molecule drug discovery process: target selection, medicinal chem
138 permeation assay (PAMPA), widely used in the drug discovery process to estimate permeability in vivo.
139 d development of nintedanib from the initial drug discovery process to the latest available clinical
140 ble approach used in medicinal chemistry and drug discovery processes to alter the properties of a pa
143 y unique scaffolds from myxobacteria for the drug discovery process, we used LC-SPE-NMR-MS techniques
144 he early hit- and lead-finding phases of the drug discovery process when larger numbers of compounds
145 e implemented at a much earlier stage of the drug discovery process, when molecular property changes
147 role of molecular imaging in the therapeutic drug discovery process will also be reviewed, as this is
148 d toxicity of drug candidates earlier in the drug discovery process will speed up the introduction of